Prevention of peanut allergy by early consumption - a prospective study.

Prevention of peanut allergy by early consumption - a prospective study. - PEAP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00005487

Enrollment

460

Registered

2014-03-25

Start date

2011-05-23

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peanut allergy T78.1 L20.9

Interventions

Group 1: frequent peanut consumption (3x/week) for 1 year Group 2: No peanut consumption for 1 year

Eligibility

Sex/Gender

All

Age

5 Months to 30 Months

Inclusion criteria

Inclusion criteria: Atopic eczema, no sensitization to peanuts, no frequent peanut consumption, written informed consent from parents

Exclusion criteria

Exclusion criteria: Lack of linguistic proficiency in German

Design outcomes

Primary

Measure	Time frame
IgE-mediated peanut allergy. In all children of the intervention and control group peanut-specific serum IgE will be determined 1 year after intervention. Sensitized children with elevated peanut-specific IgE will undergo an oral peanut challenge to determine clinical relevance.	—

Secondary

Measure	Time frame
Peanut-specific serum IgG4 determined in all children of the intervention and control group determined 1 year after intervention as a marker for tolerance	—

Countries

Germany

Contacts

Public ContactBirgit Ahrens

Charité, Universitätsmedizin BerlinKlinik für Pädiatrie m.S. Pneumologie & Immunologie Charité Campus Virchow

Kinder-allergiestudien@charite.de030 450 566 037

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026